Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J George

Showing results (11-20 of 317) with videos related to

Pageof 32
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
The future of kidney cancer treatmentDaniel J George
Gastroenterology & Hepatology|May 26, 2021
What Can We Learn From Cancer Disparities?Daniel J George
Nature Medicine|April 6, 2021
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatmentTian Zhang, Daniel J George
Cancer|December 15, 2025
What we can learn from a national tumor pathology registryJordan Infield, Daniel J George
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Tyrosine kinase inhibitors in renal cell carcinomaAnil Potti, Daniel J George
Clinical Advances in Hematology & Oncology : H&O|July 7, 2020
Choosing the best approach for patients with favorable-risk metastatic renal cell carcinomaTian Zhang, Daniel J George
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 30, 2021
Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority PopulationsMatthew Labriola, Daniel J George
Future Oncology (London, England)|August 19, 2021
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancerDaniel J George, David P Dearnaley
Expert Opinion on Investigational Drugs|September 28, 2005
Targeted therapy in renal cell carcinomaJustin P Favaro, Daniel J George
Therapeutics and Clinical Risk Management|May 14, 2008
Satraplatin in the treatment of hormone-refractory metastatic prostate cancerAndrew J Armstrong, Daniel J George
Pageof 32

Showing results (11-20 of 317) with videos related to

Sort By:
Pageof 32
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
The future of kidney cancer treatmentDaniel J George
Gastroenterology & Hepatology|May 26, 2021
What Can We Learn From Cancer Disparities?Daniel J George
Nature Medicine|April 6, 2021
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatmentTian Zhang, Daniel J George
Cancer|December 15, 2025
What we can learn from a national tumor pathology registryJordan Infield, Daniel J George
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Tyrosine kinase inhibitors in renal cell carcinomaAnil Potti, Daniel J George
Clinical Advances in Hematology & Oncology : H&O|July 7, 2020
Choosing the best approach for patients with favorable-risk metastatic renal cell carcinomaTian Zhang, Daniel J George
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 30, 2021
Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority PopulationsMatthew Labriola, Daniel J George
Future Oncology (London, England)|August 19, 2021
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancerDaniel J George, David P Dearnaley
Expert Opinion on Investigational Drugs|September 28, 2005
Targeted therapy in renal cell carcinomaJustin P Favaro, Daniel J George
Therapeutics and Clinical Risk Management|May 14, 2008
Satraplatin in the treatment of hormone-refractory metastatic prostate cancerAndrew J Armstrong, Daniel J George
Pageof 32